Scotia Foscan Shows Increased Response Rate In August Trial Update
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Updated results for the pivotal Phase II/III trial of Scotia’s photodynamic therapy Foscan (temoporfin) demonstrated a 17% complete tumor response rate and an 11% partial response rate in 64 patients with advanced, inoperable head and neck cancer. The firm reported the follow-up data at the 5th International Conference on Head and Neck Cancer August 1 in San Francisco.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class